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Background: Hepatocellular carcinoma (HCC) in young subjects is rare but more devastating. We hypothesize that
genes and etiological pathways are unique to young HCC (yHCC; ≤40 years old at diagnosis) patients. We therefore
compared the gene expression profiles between yHCCs and HCCs from elderly patients.
Results: All 44 young HCCs (≤40 years old at the diagnosis; 23 cases in the training set while another 21 in the
validation cohort) were positive for serum hepatitis B surface antigen (HBsAg), but negative for antibodies to
hepatitis C virus (anti-HCV). All 48 elderly (>40 years old; 38 in the training set while another 10 in the validation
cohort) HCC patients enrolled were also serum HBsAg positive and anti-HCV negative. Comparative genomics
analysis was further performed for elucidating enriched or suppressed biological activities in different HCC subtypes.
The yHCC group showed more macroscopic venous invasions (60.9% vs. 10.5%, p < 0.001), fewer associated cirrhosis
(17.4% vs. 63.2%, p < 0.001), and distinct profiles of expressed genes, especially those related to DNA replication and
repair. yHCCs possessed increased embryonic stem cell (ESC) traits and were more dedifferentiated. A 309-gene
signature was obtained from two training cohorts and validated in another independent data set. The ILF3 ESC
gene, which was previously reported in poorly differentiated breast cancers and bladder carcinomas, was also
present in yHCCs. Genes associated with HCC suppression, including AR and ADRA1A, were less abundant in yHCCs.
ESC genes were also more enriched in advanced HCCs from elderly patients.
Conclusion: This study revealed the molecular makeup of yHCC and the link between ESC traits and HCC subtypes.
Findings in elderly tumors, therefore, cannot be simply extrapolated to young patients, and yHCC should be treated
differently.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers worldwide and chronic hepatitis B virus
(HBV) infection is the most important cause of HCC in
Taiwan [1,2]. Most HCC patients are diagnosed in old age
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reproduction in any medium, provided the orold [1,2]. Compared with the elderly HCC patients, young
HCC (yHCC) cases (≤40 years of age) are more likely to
be symptomatic at diagnosis and the HCC stage tends to
be more advanced. Thus, there is a decreased chance of
curative resection for the tumors in this group [3,4]. Al-
though the presence of cirrhosis is less frequent in young
patients [4], the time to yHCC recurrence after surgical
resection was shorter and a one year survival rate was
lower than those with elderly patients [4,5]. An aggressive
clinical course and a poor prognosis have also been re-
ported in children with HCC [6,7]. If yHCC patientstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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seemed to be better than those of elderly HCC patients
due to fewer incidences of associated cirrhosis and rela-
tively better liver function reserves [5]. High serum alpha-
fetoprotein levels are more often found in yHCC patients
[3,8]. HBV viral load is not a predictor in the development
of HCC in young adults [9-11], in contrast, viral load and
hepatic inflammatory activity were associated with
late recurrence of HCC among elderly patients after re-
section of the primary HCC [12]. The aforementioned
findings suggest that hepatocarcinogenesis in yHCCs is
different from that in elderly patients. Yet the underlying
mechanisms and the detail molecular portrait of yHCC re-
main unclear.
It has also been recognized that cancer cells, especially
those of advanced and metastatic cancers, possess char-
acteristics reminiscent of normal stem cells. The degree
of stem cell gene reactivation or tumor cell dedifferenti-
ation correlates with pivotal tumor features and progno-
sis [13,14]. A recent paper demonstrated by RT-qPCR, that
the high expression levels of putative hepatic stem/pro-




Age (years) (median; 25 and 75 percentiles) (range) 47.5; 36.5-6
(26-75.7)
Sex (M:F) 54:7
Albumin (g/dL) (median; 25 and 75 percentiles) 4.0; 3.8-4.4
Total bilirubin (mg/dL) (median; 25 and 75 percentiles) 0.80; 0.6-1.2
ALT (U/L) (median; 25 and 75 percentiles) 41.0; 30.5-5
AST (U/L) (median; 25 and 75 percentiles) 40.0; 27.0-6
Platelet (/mm3) (median; 25 and 75 percentiles) 182000;
139000-224
ICG-15R (%) (retention rate) (median; 25 and 75 percentiles) 8; 5.3-12.8
Child-Pugh A/B (%) 59/2 (96.7%
Tumor characteristics
Tumor size (cm) (median; 25 and 75 percentiles) 4.8; 3.4-8.7
Multinodularity (%) 28 (45.9%)
AFP (ng/ml) (median; 25 and 75 percentiles) 190; 15-154
Macroscopic venous invasion (%) 18 (29.5%)
Daughter nodule (%) 32 (62.8%)
Histopathological findings
Cirrhosis in non-tumor part (yes/no) (%) 33/28 (54.1
Edmondson grading (I or II/ III or IV) (%) 33/24 (57.9
Microscopic venous invasion (%) 43 (70.5%)
ICG-15R: indocyanine green retention rate at 15 minutes;
*p value: comparison between younger and elderly HCC patients.and a poor prognosis for HCC [15]. However, no similar
study has addressed yHCC. Identifying genes involved in
cancer progression and cell dedifferentiation offers another
dimension to predict HCC recurrence, as well as providing
novel therapeutic targets and prognosis markers.
Results
Clinical profiles, serological data, and histopathological
findings for the HCCs from young and elderly patients
enrolled in array analysis
The clinical profiles, serological data, and histopathological
findings for young and elderly HCC patients in the training
cohort are in Table 1. In 61 enrolled primary HBsAg posi-
tive HCC patients, 23 cases were yHCCs and 38 were eld-
erly. Macroscopic venous invasion was more frequent
(60.9% vs. 10.5%, p < 0.001), but accompanied cirrhosis was
significantly fewer in younger subjects (17.4% vs. 63.2%,
p < 0.001). Consistent with fewer cirrhotic patients in
the younger group, the ICG-15 retention was lower (p =
0.0055) and the platelet counts tended to be higher (p =
0.087). There were no statistically significant differences in
the remaining parameters between these two groups.ohort HCC patients undergoing surgical resection
s Age ≦40 Age >40 p*







4.2; 3.9-4.4 4.0; 3.7-4.3 0.129
0.7; 0.5-1.1 0.9; 0.6-1.2 0.688
7.0 46.0; 35.0-61.0 38.0; 29.8-57.0 0.946







6; 4-8 10; 6-14.3 0.0055
/3.3%) 22/1 (95.7%/4.4%) 37/1 (97.4%/2.6%) 1.000
5.0; 4.0-11.0 4.4; 3.2-6.4 0.523
9 (39.1%) 19 (50.0%) 0.440
1 316; 18.4-5499 169.5; 12.9-728.5 0.742
14 (60.9%) 4 (10.5%) <0.001
11 (55.0%) 21 (67.7%) 0.389
%/45.9%) 4/19 (17.4%/82.6%) 24/14 (63.2%/36.8%) <0.001
%/42.1%) 11/12 (47.8%/52.2%) 22/12 (64.7%/35.3%) 0.276
17 (73.9%) 26 (68.4%) 0.775
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Data analysis steps were summarized in Additional file 1:
Figure S1 online. To explore the molecular mechanisms
governing the diverse clinical behaviors of the different
HCCs, we delineated gene expression profiles of 48 pri-
mary HCC samples, as well as those of 39 non-cancerous
tissues, from the above 61 patients as a training data set.
A multidimensional scaling (MDS) plot using the whole
transcriptome showed that the mRNA profiles of normal
and cancerous tissues were different, while tumors of dif-
ferent age groups were similar (Figure 1A). We compared
tumor samples to non-tumor counterparts for minimizing
stromal and myometrial contamination. A total of 449
probe sets were differentially expressed between young
and elderly HCCs (positive false discovery rate (pFDR)A B


























Figure 1 Distinct gene expression patterns in HCC from young or eld
whole transcriptome illustrates the mRNA profiles of normal and cancerous ti
between the HCC tumor tissues of young and elderly patients, or between tu
using a machine learning strategy and an independent testing elderly HCC d
the top 309 features was the largest panel to give the lowest error rate (i.e., a
309-probeset signature on the validation data set. The prediction strength plo
identified 309 probe sets in separating young and elderly patients in the valid
young and elderly HCCs in the training data set 1, as well as discriminating tu
represent probe sets. Genes in red: increased; in blue: decreased. Genes undeq < 0.05), as well as between tumor and non-tumor tissues
of yHCC patients (Figure 1B).
The discrimination ability of these 449 probe sets were
further trained by performing supervised machine learn-
ing that combined weighted voting algorithm and leave-
one-out cross validation (LOOCV) [16], on the 2nd
external data set (downloaded from the Expression Project
for Oncology (expO)). An error rate of 9.4% (2 out of 16
yHCCs and 1 out of 16 elderly HCCs in the validation
set; P < 0.001 by permutation test) was found (Figure 1C).
The top 309 features (ranked by the weighted value of
each probe set [16]) form a largest panel to have the best
discrimination ability than that of the 449-probeset sig-
nature (error rate 0 vs. 9.4%; Figure 1C, upper panel).












APAF1, ARV1, BCOR, MSH5, CABIN1, CAD, 
CCDC131, CDC25A, CDC2L6, CHD8, CKAP4
CREBZF, CTNND2, DEPDC1B, DNMT1, DYNC1H1
EIF3D, ETV4, FAM118A, FAM60A, FANCA, FANCI
FBLIM1, FKBP14, FUBP1, FUS, GAS2L3, GGA1
GGA3, GK5, GLS, GRB7, GTPBP1, GTSE1, HIC2
HNRNPA3, HNRNPUL1, ILF3, KCNQ1OT1, KLHL29
KPNB1, L3MBTL, LIG1, TNRC18, LZTS2, MAP4K4
MATR3, MED12, MESDC1, MGA, MLL, MLL2, 
MORC2, MRE11A, MYLIP, NAP1L1, NCOR2, 
NONO, NUPL1, OBFC2B, OFD1, P15RS, PABPC1L, 
PATZ1, PHF21A, PI4KA, PLEKHG2, POLDIP3, 
POLQ, PPP1CA, PRPF19, RAB34, RAD1, RAI1, 
RBBP4, RBL1, RCC1, RDH11, RP4-691N24.1, 
RPL10, RPLP1, RPS8, SART3, SBNO1, SLFN13, 
SMARCA4, SMARCB1, SMARCC1, SMARCC2, 
SOX13, SPATA5L1, SPATS2, SPIN3, SPINT1, 
SSRP1, STK38, SUZ12, SUZ12P, TCF20, TDG, 
TFCP2, THAP2,TLE3, TMED3, TMEM5, TOP3B, 
TRIM11, TRIM59, TUG1, TWF1, UBTF, UTP20, 










erly patients. (A) A multidimensional scaling (MDS) plot using the
ssues. (B) A Venn diagram summarizing genes differentially expressed
mor and non-tumor yHCC samples. (C) Advanced signature training
ata set. When probe sets were ranked by signal-to-noise ratios (weights),
best classification effect; upper panel). (D) The discrimination ability of the
t (upper) and the PCA plot (lower) show the discriminating power of the
ation cohort. (E) A heat map shows the 309 probes sets differentiating
mor and non-tumor tissues. Columns represent tumor samples; rows
rlined: discussed in the text.
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another 21 yHCCs and 10 Taiwanese elderly HCCs (4 were
at T1 stage and the remaining 6 were at T3 stage by 6th
edition American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) staging system
[17,18]). Prediction strength (PS; Figure 1D, upper) and
principle component analysis (PCA; Figure 1D, lower)
plots showed that these 309 probe sets distinguished young
and elderly HCCs well.
The distribution of these 309 probe sets among sample
groups were examined by hierarchical clustering. The
differences in gene expression profiles between elderly
and yHCC were more striking in tumor parts as com-
pared to those in non-tumor parts (Figure 1E). A heat
map for these genes indicated the unique gene expres-
sion levels in yHCC, with 225 probe sets being predom-
inantly up in yHCCs (Table 2) while another 84 being
down (Figure 1E). Many of yHCC-enriched genes, such
as CTNND2 (delta 2 catenin), RAB34 (a member of
the RAS oncogene family), SOX13 (SRY (sex deter-
mining region Y)-box 13), ETV4 (ets variant gene 4),
DNMT1 (DNA cytosine-5-methyltransferase 1), TLE3
(transducin-like enhancer of split 3), MLL (myeloid/
lymphoid or mixed-lineage leukemia), and MLL2, have
been associated with tumor malignancy and poor patient
outcomes in HCC or other cancers (Figure 1E, under-
lined). These consistent findings support the reliability of
our gene list. Genes down-regulated in yHCC (i.e. more
abundant in elderly HCCs) are shown in Additional file 2:
Table S1.
Coordinated functional module changes in yHCCs
To understand how genes enriched in yHCC are related
to each other, as well as to spot the more critical yHCC
genes, we performed systems biology analysis. A major
genetic network contains known cancer-related or pro-
proliferating genes, including CDC25A, CDK19, FUS
(fused in sarcoma), TLE3, and ILF3 (interleukin enhancer
binding factor 3) was formed (Figure 2A). Central to the
network, there were hub genes (genes with higher connect-
ivity to others), including MLL, SMARCA4, SMARCB1,
SMARCC1, and RBBP4 (retinoblastoma binding protein 4)
(Figure 2A).
To understand better how gene expression profiles
correlate with pathogenesis and tumor phenotypes, sig-
nature probe sets were subjected into canonical path-
ways and functional group analysis using the Ingenuity
Pathway Analysis (IPA) and Gene Ontology (GO) data-
bases, respectively. The most significant canonical path-
way mapped is the “BRCA1 in DNA Damage Response”
pathway (Figure 2B). Other predominant pathways were
DNA double-strand break repair, DNA methylation and
transcriptional repression and ATM Signaling (Figure 2B).
Consistent with the unique expression profile of yHCCs,the genes involved in the regulation of transcription were
enriched in yHCCs (p = 5.84*10e-05; Figure 2C, panel 1).
Genes involved in chromatin modification are also unique
in yHCCs (p = 1.36*10e-5; Figure 2C, panel 3). Other re-
lated predominant GO processes included those pertain-
ing to DNA repair (p = 5.11*10e-5) and M phase cell cycle
(p = 2.00*10e-4) (Figure 2C, panels 2–3).
Increased embryonic stem cell (ESC) traits in HCCs,
especially those from young patients
Stemness genes are known to contribute largely in
tumorigenesis and disease progression [13,14]. For nar-
rowing down key genes and obtaining more insights in
yHCC pathogenesis, the above 309 probe sets were used
to compare the relationships between HCCs and ESC.
Transcriptome distances were measured by calculating
the average linkage distances. Compared with non-tumor
tissues, HCCs of different age categories were closer to
ESCs (Figure 3A), suggesting the re-expression of ESC
genes is a characteristic feature during tumorigenesis. The
closest correlation between ESC and yHCC was observed,
indicating the level of ESC gene re-expression was in-
versely correlated with patient age (Figure 3A).
The distributions of these 309 probe sets among sample
groups were shown using a heat map (Figure 3B). Among
genes enriched in yHCC, a subgroup of genes was also
abundant in stem cells, especially in ESC (Figure 3B).
Table 2 shows ESC genes overexpressed in YHCC pa-
tients. Among them, 9 genes were involved in cell cycle
control (CDC25A, DYNC1H1, FANCI, GTSE1, HELLS,
ILF3, LIG1, LZTS2, and RCC1; p = 1.3*10e-3, gene enrich-
ment analysis was done based on the GO database), 5
genes in DNA repair (FANCI, PRPF19, LIG1, NONO, and
SSRP1; p = 8.3*10e-3), and 2 genes in blastocyst growth
(PRPF19 and SMARCA4; p = .031) (Table 2, genes with
asterisks). Intriguingly, ILF3 is among the ‘Core 9’ ESC
transcription regulators that were highly expressed in
poorly differentiated breast cancers, glioblastomas, and
bladder carcinomas (13). The differential expression of
ILF3 between young and elderly HCCs was verified by
RT-qPCR (Figure 3C).
Decreasing hepatic differentiation program in yHCCs and
during disease progression in elderly HCCs
We hypothesized that yHCCs also forfeited genes associ-
ated with liver differentiation and thereby were more
dedifferentiated and malignant. Liver precursor charac-
teristics were examined in the yHCC samples by com-
paring the relationships between HCC subgroups and
liver progenitor cells (derived from the H9 ESC line
[19]). An inverse correlation between the hepatogenesis
process with patient ages was observed (Figure 4A, left
panel; the direction of ESC hepatogenesis is indicated by
a green arrow). Such impressions were strengthened by
Table 2 ESC genes overexpressed in yHCC patients (q < 0.05, Young HCC vs. elder HCC)
Probe set ID UniGene ID Gene title Gene symbol Location Folds
219010_at Hs.518997 chromosome 1 open reading frame 10 C1orf106 chr1q32.1 3.05
202715_at Hs.377010 carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase
CAD chr2p22-p21 1.68
1555772_a_at Hs.437705 cell division cycle 25 homolog A (S. pombe) *CDC25A chr3p21 1.89
226980_at Hs.482233 DEP domain containing 1B DEPDC1B chr5q12.1 2.08
201697_s_at Hs.202672 DNA (cytosine-5-)-methyltransferase 1 *DNMT1 chr19p13.2 1.74
229115_at Hs.649497 dynein, cytoplasmic 1, heavy chain 1 *DYNC1H1 chr14q32.3-qter 1.78
200005_at Hs.55682 eukaryotic translation initiation factor 3, subunit D EIF3D chr22q13.1 1.55
1554576_a_at Hs.434059 ets variant gene 4 (E1A enhancer binding protein, E1AF) ETV4 chr17q21 2.02
220060_s_at family with sequence similarity 222, member B FAM222B chr17q11.2 1.56
213008_at Hs.513126 Fanconi anemia, complementation group I *FANCI chr15q26.1 1.78
219390_at Hs.571333 FK506 binding protein 14, 22 kDa FKBP14 chr7p15.1 1.72
223079_s_at Hs.116448 glutaminase GLS chr2q32-q34 2.26
215942_s_at Hs.386189 G-2 and S-phase expressed 1 *GTSE1 chr22q13.2-q13.3 1.94
242890_at Hs.655830 Helicase, lymphoid-specific *HELLS chr10q24.2 2.47
212966_at Hs.632767 hypermethylated in cancer 2 *HIC2 chr22q11.21 2.71
208930_s_at Hs.465885 interleukin enhancer binding factor 3, 90 kDa *ILF3 chr19p13.2 2.32
208974_x_at Hs.532793 karyopherin (importin) beta 1 KPNB1 chr17q21.32 1.82
202726_at Hs.1770 ligase I, DNA, ATP-dependent *LIG1 chr19q13.2-q13.3 1.82
65588_at Hs.400876 lncRNA LOC388796 LOC388796 65588_at 1.68
224473_x_at Hs.523221 leucine zipper, putative tumor suppressor 2 *LZTS2 chr10q24 1.61
64432_at Hs.333120 MAPKAPK5 antisense RNA 1 MAPKAPK5-AS1 chr12q24.12 1.61
242260_at Hs.268939 Matrin 3 MATR3 chr5q31.2 2.35
235409_at Hs.187569 MAX gene associated MGA chr15q14 1.79
228097_at Hs.484738 myosin regulatory light chain interacting protein MYLIP chr6p23-p22.3 1.64
208752_x_at Hs.524599 nucleosome assembly protein 1-like 1 NAP1L1 chr12q21.2 1.66
214107_x_at Hs.740414 aminopeptidase puromycin sensitive NPEPPS chr17q21 1.85
200057_s_at Hs.533282 non-POU domain containing, octamer-binding *NONO chrXq13.1 1.52
228566_at Hs.464912 Cyclin-dependent kinase 2B-inhibitor-related protein P15RS chr18q12.2 1.51
203103_s_at Hs.502705 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) *PRPF19 chr11q12.2 1.49
1555630_a_at Hs.301853 RAB34, member RAS oncogene family RAB34 chr17q11.2 3.14
206499_s_at Hs.469723 regulator of chromosome condensation 1 *RCC1 chr1p36.1 1.59
200858_s_at Hs.512675 ribosomal protein S8 RPS8 chr1p34.1-p32 1.36
209127_s_at Hs.584842 squamous cell carcinoma antigen recognized by T cells 3 SART3 chr12q24.1 2.03
214728_x_at Hs.327527 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, a4
*SMARCA4 chr19p13.2 1.61
201072_s_at Hs.476179 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, c1
SMARCC1 chr3p23-p21 1.89
228990_at Hs.632377 small nucleolar RNA host gene 12 (non-protein coding) SNHG12 chr1p35.3 1.86
218324_s_at Hs.654826 spermatogenesis associated, serine-rich 2 SPATS2 chr12q13.12 1.84
202826_at Hs.233950 serine peptidase inhibitor, Kunitz type 1 SPINT1 (HAI-1) chr15q15.1 3.36
200956_s_at Hs.523680 structure specific recognition protein 1 *SSRP1 chr11q12 1.78
207627_s_at Hs.48849 transcription factor CP2 TFCP2 chr12q13 1.66
212770_at Hs.709205 transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) TLE3 chr15q22 1.51
208837_at Hs.513058 transmembrane emp24 protein transport domain containing 3 TMED3 chr15q24-q25 2.77
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Table 2 ESC genes overexpressed in yHCC patients (q < 0.05, Young HCC vs. elder HCC) (Continued)
238797_at Hs.13543 tripartite motif-containing 11 TRIM11 chr1q42.13 1.51
235476_at Hs.212957 tripartite motif-containing 59 TRIM59 chr3q26.1 2.00
209053_s_at Hs.113876 Wolf-Hirschhorn syndrome candidate 1 WHSC1 chr4p16.3 1.97
204799_at Hs.475208 zinc finger, BED-type containing 4 ZBED4 chr22q13.33 1.72
228988_at Hs.326801 zinc finger protein 711 ZNF711 chrXq21.1-q21.2 3.40
*Genes discussed in the text.
Wang et al. BMC Genomics 2013, 14:736 Page 6 of 11
http://www.biomedcentral.com/1471-2164/14/736calculating the transcriptome distances between the
sample groups (Figure 4A, right panel). Among the
309 yHCC genes, 15 genes were more abundant in differ-
entiated liver progenitor cells (day 20; Additional file 3:
Figure S2 online). These 15 genes, which are also down-
regulated in yHCCs, hold the potentials of being novel
tumor suppressor genes in yHCCs.
The above observation inspired us to hypothesize fur-
ther that the forfeiting of hepatogenesis traits may have
also occurred during disease progression in HCCs of the
same age group. We examined the associations between
ESC gene patterns and clinical stage. Early (T1) and late
(T3) HCCs [18] used in the validation cohort were ap-
plied to compare the relationships with ES cells and the
advanced T3 cases were closer to ES cells (Figure 4B).
Such relationships were validated by evaluating another
independent serum anti-HCV positive HCC data set
[20]. This data set included four neoplastic stages (very
early HCC to very advanced metastatic tumors) from pa-
tients with HCV infection [20]. When the relationships
between the different pathological HCC subgroups and
pluripotent stem cells (including ESCs and induced
pluripotent stem cells (iPS cells) [19]) were compared,
an increased stemness that accurately reflected the
pathological progression of the disease was again ob-
served (Figure 4C). A dedifferentiation-like transcrip-
tome drift (indicated by an orange arrow, Figure 4C)
was anti-correlated with the hepatic differentiation pro-
gram of pluripotent stem cells (indicated by a green
arrow), indicating a dedifferentiation status during the
progression of HCV-related HCC.
Discussion
This study explored the gene expression profile of
yHCC. We found the age difference between HCC pa-
tients is mirrored in their gene expression profiles. A
similar observation has been reported for other cancers:
there was a clear segregation of the pediatric and adult
germ cell tumors [21], and pediatric glioblastomas also
have a characteristic transcriptome profile different from
that of adult tumors [22,23]. The outcomes of melanoma
in the younger and the elderly populations were also dif-
ferent and these 2 patient groups express distinct micro-
RNA profiles [24]. Thus, age difference between patientswith the same disease can be mirrored in their gene ex-
pression profiles. Patients of different ages but with the
same tumor should be treated in different ways.
Gender disparity is a well known phenotype in HCC,
and animal studies suggest that it may be due to the
stimulatory effects of androgen and the protective effects
of estrogen (see reviews [25,26]). Estrogen can protect
hepatocytes from malignant transformation [27]. Intri-
guingly, both the androgen receptor (AR) and estrogen
receptor 1 (ESR1) sex hormone receptors are down-
regulated in yHCCs (Additional file 2: Table S1 & not
shown). Genes involved in estrogen receptor signaling
are also enriched in the yHCC signature (Figure 2B).
Since all of our yHCC patients were sexually matured
(the youngest case is a 26-year old female; Table 1), our
data indicates an original and a unique pathogenesis
mechanism in yHCCs.
HCC with stemness-related marker expression has
recently been proposed to be a new and more aggres-
sive subtype of HCC [28,29]. It is important that a
suitable marker panel is developed to facilitate the
diagnosis of this devastating HCC subtype. RT-qPCR
analysis on elderly HCCs demonstrated that the high
expression levels of 7 putative hepatic stem/progenitor cell
biomarkers (including keratin 19 (K19), ABCG2, CD44,
Nestin, CD133, EPCAM and OV6), is related to tumor
angiogenesis and a poor prognosis for the HCC [15,28].
Recently, a stemness-related marker, CK19, was found
well correlated with clinicopathologic features of tumor
aggressiveness, vascular invasion, and poor differentiation
in elderly HCCs [30]. No similar study has been addressed
on yHCCs. Identifying genes involved in both cancer
progression and cell dedifferentiation will offer another
dimension to pathogenesis mechanisms, as well as provid-
ing novel therapeutic targets and prognosis markers. ILF3
(NF90) is one of the shared top genes between ESC and
yHCC. LIF3 is among the ‘Core 9’ ESC genes highly re-
expressed in advanced and poorly differentiated tumors
[13] and is a prognostic factor in non-small cell lung can-
cer [31]. Another ESC gene overexpressed in yHCCs is
DNMT1 and is responsible for the maintenance of DNA
methylation patterns during replication. Inhibitors of this
enzyme may potentially lead to DNA hypomethylation
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Figure 2 Interaction network and gene set enrichment analyses as frameworks for interpreting yHCC biology. (A) A genetic network
composed of multiple yHCC genes. This network is displayed graphically as nodes (gene products) and edges (biological relationships between
nodes) mapped by the Ingenuity Pathway Analysis (IPA) tool. The intensity of the node color indicates the degree of upregulation. (B) Canonical
pathway analysis. Genes that are more abundant in yHCC were subjected to IPA search. (C) Altered biological modules in yHCCs. 282 probe sets
that are more abundant in yHCC were subjected to Gene Ontology database search. The number of genes, gene symbols, and p values for each
category that are significantly enriched are listed (p < 0.05).




















































Figure 3 ESC traits in yHCCs. (A) Relationships between ESC, HCCs of different ages, and non-tumor tissues. Average linkage distances between tissues
and ESC were calculated using the filtered 309 probe sets. The confidence limits as shown represent the standard error. YT and T: cancerous HCC samples
from young and elderly patients, respectively. YN and N: non-tumor samples. (B) A heat map showing shared genes between yHCC and ESC. (C) Validation
of ILF3 array data by real-time RT-PCR. The mean expression levels of the target genes were compared to the GAPDH control. **: p< 0.01 by t-test.
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cial in HCC pathogenesis and cancer stem cell renewal
[34]. Targeting these genes or pathways may restrain inva-
sion by yHCC.
In addition to stemness genes, we also filtrated out 15
differentiation-related genes from in yHCCs. Eleven of
these genes, including GSTK1 (glutathione S-transferase
kappa 1) and SAR1B (SAR1 gene homolog B), are within
the top 50 most down-regulated genes in yHCC patients
(Additional file 2: Table S1; labeled with asterisks in
Additional file 3: Figure S2). The repressed transcript
levels and increased gene expression patterns during
ESC hepatogenesis implied that these genes might func-
tion as novel tumor suppressor genes (TSGs). GSTK1
belongs to the glutathione S-transferase (GST) gene
family that are critical for detoxification via conjugation
of reduced glutathione (GSH) with numerous substrates
such as pharmaceuticals and environmental pollutants
[35]. GSTP1, another member of the GST family, has
recently been identified to be a novel TSG for elderly
HCCs, and the methylation frequency in GSTP1 is as-
sociated with HCC occurrence [36]. Roles of GSTK1
in yHCCs tumorigenesis and prognosis, as well as in
ESC hepatogenesis, are awaited to be elucidated in
the future.
Conclusion
This study revealed the molecular makeup of yHCC and
the link between ESC traits and HCC subtypes. There-
fore, molecular mechanisms in elderly HCC patients
cannot be simply extrapolated to younger patients. Our
results also helped to identify transcriptional programs
that can be used as potential therapeutic targets for vari-
ous HCC subgroups.Methods
Patient profiles and microarray expression data sets
Data analysis and RNA isolation details were summa-
rized in Additional file 4: Supplementary Materials and
Methods online. The diagnosis of all the HCC patients
had been tissue-verified by pathological examination of
the surgically removed HCC and neighboring liver tis-
sue. All 44 young HCCs (≤40 years old at the diagnosis;
23 cases in the training set while another 21 in the valid-
ation cohort) were positive for serum hepatitis B surface
antigen (HBsAg), but negative for antibodies to hepatitis
C virus (anti-HCV). All 48 elderly (>40 years old; 38
in the training set while another 10 in the validation
cohort) HCC patients enrolled were also serum HBsAg
positive and anti-HCV negative. The HCC samples used
in this study were the original tumors obtained from
the first operations of patients. The current study com-
plies with the Helsinki Declaration. Informed consents
for taking small part of the resected HCC and the
surrounding non-tumor liver specimens for study were
obtained from patients. The tissue sample analysis was
approved by the Institutional Review Board of Taipei
Veterans General Hospital (VGHIRB No.: 97-09-17A),
Taiwan.
Fresh HCC tissues and non-tumor counter parts
that had been removed during surgery were snap fro-
zen and kept in liquid nitrogen for RNA extraction.
All array data were deposited into the NCBI Gene ex-
pression omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/) database [37] with the accession number GSE45436
(see Additional file 1: Figure S1; training set 1 GSE45267,
training set 2 GSE45434, and validation set GSE45435).
The embryonic stem cell (ESC) array data had been
































































































Figure 4 Decreased hepatogenesis characters in yHCCs but increased ESC traits in advanced HCCs. (A) Forfeiting of liver differentiation
program in yHCCs. (Left) A PCA plot using genes differentiating the H9 ESCs and day 20 hepatic differentiated progenies (q < 10-4). The
transcriptome drift directions during hepatic differentiation are indicated by an arrow. Hepatic_ESC: day 20 (d20) hepatic differentiated progenies.
(right) Relationships between liver precursors and HCCs of different age groups. (B) Relationships between ESC and HCC of different
histopathological stages. (Left) A PCA plot based on 977 probe sets genes distinguishing early (T1) and late (T3) HCCs from elderly patients. (Right)
Relationships between ESC and T1/T3 HCCs. (C) Dedifferentiation-like transcriptome reprogramming during the progression of HCV-related HCC.
(Left) A PCA plot using genes differentiating very early (ve) and advanced (a) HCC (q < 0.01, 1700 probe sets). The orange arrow represents the
transcriptome drift direction during HCC progression. eHCC, early HCC; aHCC, advanced HCC; Hepatic_iPS cells: day 20 hepatic differentiated
progenies of iPS cells. (Right) Relationships between ESC and HCC at different clinical stages.
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GSE6764) [20]. Array data of the induced pluripotent
stem cells (iPS cells) and ESCs, as well as their hepatic dif-
ferentiated progenies, were from GEO dataset GSE14897
[19]. The second batch of elderly HCCs of the training
data set were downloaded from the Expression Project
for Oncology (expO) of the International Genomics
Consortium (http://www.intgen.org/, accession num-
ber GSE2109 in the GEO database).Additional files
Additional file 1: Figure S1. A workflow summarizing experimental
design and the filtration of yHCC genes.
Additional file 2: Table S1. Top 50 genes down-regulated in yHCC
patients (q < 0.05, Young HCC vs. elder HCC).Additional file 3: Figure S2. Differentiation-related yHCC genes. A
Venn diagram illustrates that 83 ESC hepatogenesis-related yHCC genes
are also present in the 309 yHCC genes. A heat map based on these 83
genes is shown. Array data of H9 ESC and differentiated liver precursor
cells (day 20, d20) [19] were from GEO dataset GSE14897. *: genes
discussed in the text.
Additional file 4: Supplementary Materials and Methods.Abbreviations
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